摘要
目的:系统评价康莱特联合肝动脉介入治疗中晚期原发性肝癌的有效性和安全性。方法:计算机检索Cochrane Li brary、PubMed、EMBASE、中国生物医学文献数据库、中国期刊全文数据库、中文科技期刊全文数据库,同时手检相关期刊和会议论文集,纳入有关的随机对照试验,纳入康莱特联合肝动脉化疗栓塞治疗中晚期原发性肝癌的随机对照试验(RCTs)。结果:共检索到纳入标准的中文文献9篇(598例患者)。通过比较近期疗效及安全性,与单纯血管介入治疗相比,康莱特联合肝动脉介入治疗中晚期原发性肝癌可以改善近期疗效,包括提高临床有效率(CR+PR)、临床获益率(CR+PR+SD),还总体改善临床症状,如缓解肝区疼痛、腹胀、乏力,提高KPS评分,降低AFP指标,且不良反应发生率低,缓解白细胞及血小板降低。在半年及1年生存期的提高上,虽然分析显示没有明显的统计学意义,但临床意义提示可延长患者的生存期。结论:康莱特联合肝动脉介入治疗中晚期原发性肝癌可提高患者治疗的近期疗效,改善临床症状、提高生活质量,同时亦可改善化疗的毒副作用,一定程度上延长生存期的趋势。
Objective To evaluate the effectiveness and safety of KLT plus hepatic arterial intervention for unresectable hepatocellular carcinoma compared with hepatic arterial intervention alone.Methods The Cochrane Library,PubMed,EMBASE,CBM,CNKI and VIP were searched electronically.Relevant journals and conference proceedings were also hand searched.Relevant randomized controlled trials（RCTs） of KLT plus hepatic arterial intervention for unresectable hepatocellular carcinoma were collected.Results Nine RCTs,all published in China,involving 598 patients were included.Meta-analyses showed that： KLT plus hepatic arterial intervention,compared with hepatic arterial intervention alone,could significant benefit in clinical efficient（CR＋PR） and Clinical benefit rate（CR＋PR＋SD）,im proving clinical symptoms,such as hepatalgia,abdominal distention,feeble,improving KPS scores,reducing AFP level and the inci dence of adverse reactions.One-year and six months survival rate also improved in some extent.Conclusion KLT plus hepatic arterial intervention for unresectable hepatocellular carcinoma could improve curative effect and the quality of life of patients.Besides,it also can help improving bone marrow suppression,and reducing the adverse reactions of hepatic arterial intervention,improving the survival rate to a certain degree.
出处
《江西中医学院学报》
2012年第6期33-39,共7页
Journal of Jiangxi College of Traditional Chinese Medicine
关键词
康莱特
原发性性肝癌
动脉介入
系统评价
KLT
Primary Hepatic Carcinoma
Hepatic Arterial Intervention
Meta-analysis
